JP2021517132A5 - - Google Patents

Info

Publication number
JP2021517132A5
JP2021517132A5 JP2020546962A JP2020546962A JP2021517132A5 JP 2021517132 A5 JP2021517132 A5 JP 2021517132A5 JP 2020546962 A JP2020546962 A JP 2020546962A JP 2020546962 A JP2020546962 A JP 2020546962A JP 2021517132 A5 JP2021517132 A5 JP 2021517132A5
Authority
JP
Japan
Prior art keywords
optionally substituted
virus
alkyl
different
aryl
Prior art date
Application number
JP2020546962A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019173602A5 (https=
JP7371931B2 (ja
JP2021517132A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/021168 external-priority patent/WO2019173602A1/en
Publication of JP2021517132A publication Critical patent/JP2021517132A/ja
Publication of JPWO2019173602A5 publication Critical patent/JPWO2019173602A5/ja
Publication of JP2021517132A5 publication Critical patent/JP2021517132A5/ja
Priority to JP2023176993A priority Critical patent/JP7786743B2/ja
Application granted granted Critical
Publication of JP7371931B2 publication Critical patent/JP7371931B2/ja
Priority to JP2025207111A priority patent/JP2026062641A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020546962A 2018-03-07 2019-03-07 ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 Active JP7371931B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023176993A JP7786743B2 (ja) 2018-03-07 2023-10-12 ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用
JP2025207111A JP2026062641A (ja) 2018-03-07 2025-11-27 ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862639725P 2018-03-07 2018-03-07
US62/639,725 2018-03-07
PCT/US2019/021168 WO2019173602A1 (en) 2018-03-07 2019-03-07 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023176993A Division JP7786743B2 (ja) 2018-03-07 2023-10-12 ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用

Publications (4)

Publication Number Publication Date
JP2021517132A JP2021517132A (ja) 2021-07-15
JPWO2019173602A5 JPWO2019173602A5 (https=) 2022-03-14
JP2021517132A5 true JP2021517132A5 (https=) 2022-03-14
JP7371931B2 JP7371931B2 (ja) 2023-10-31

Family

ID=67846796

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020546962A Active JP7371931B2 (ja) 2018-03-07 2019-03-07 ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用
JP2023176993A Active JP7786743B2 (ja) 2018-03-07 2023-10-12 ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用
JP2025207111A Pending JP2026062641A (ja) 2018-03-07 2025-11-27 ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023176993A Active JP7786743B2 (ja) 2018-03-07 2023-10-12 ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用
JP2025207111A Pending JP2026062641A (ja) 2018-03-07 2025-11-27 ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用

Country Status (14)

Country Link
US (2) US20210308168A1 (https=)
EP (1) EP3762372A4 (https=)
JP (3) JP7371931B2 (https=)
KR (2) KR20260028884A (https=)
CN (2) CN112074506B (https=)
AU (2) AU2019231725B2 (https=)
BR (1) BR112020018209A2 (https=)
CA (1) CA3093222A1 (https=)
EA (1) EA202092117A1 (https=)
GB (2) GB2611644B (https=)
IL (1) IL277160B2 (https=)
PH (1) PH12020551404A1 (https=)
SG (1) SG11202008527WA (https=)
WO (1) WO2019173602A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
JP6804790B1 (ja) 2017-12-07 2020-12-23 エモリー ユニバーシティー Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
US20210353660A1 (en) * 2018-10-04 2021-11-18 Octagon Therapeutics Inc. Pre-Activated Nucleoside IMPDH Inhibitors As Anti-Infective Drugs
AU2020418425A1 (en) * 2019-10-08 2022-04-14 Emory University 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CA3176661A1 (en) * 2020-04-24 2021-10-28 Memorial Sloan-Kettering Cancer Center Targeted therapy for the treatment & prevention of life-threatening complications of infection
EP4203970A4 (en) * 2020-08-27 2025-03-26 Emory University NEW FORMS OF ANTIVIRAL NUCLEOSIDES
CN114644666B (zh) * 2020-12-18 2026-03-03 上海特化医药科技有限公司 5’-核苷前药的制备方法及中间体
WO2022133205A1 (en) * 2020-12-18 2022-06-23 Merck Sharp & Dohme Corp. Synthesis of antiviral nucleosides
CN112608357B (zh) * 2020-12-21 2022-12-09 杭州科巢生物科技有限公司 一种抗病毒药物Molnupiravir的制备方法
CN112778387A (zh) * 2021-01-15 2021-05-11 杭州科巢生物科技有限公司 一种Molnupiravir晶型A及其制备方法
WO2022174194A1 (en) * 2021-02-15 2022-08-18 Emory University 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2022174179A1 (en) * 2021-02-15 2022-08-18 Emory University 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
EP4319763A4 (en) * 2021-04-09 2025-06-11 Emory University MODIFIED NUCLEOSIDES AND NUCLEOTIDE ANALOGUES AS ANTIVIRAL AGENT FOR CORONAVIRUS AND OTHER VIRUSES
US20240166680A1 (en) * 2021-04-15 2024-05-23 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Nucleoside analog and use thereof
US11407779B1 (en) 2021-04-23 2022-08-09 Divi's Laboratories Ltd. Process for the preparation of molnupiravir
CN112979733B (zh) * 2021-04-25 2021-09-10 南京颐媛生物医学研究院有限公司 抗乙肝病毒的化合物及其制备方法和应用
US20250281519A1 (en) * 2021-05-05 2025-09-11 Emory University Nucleotide and nucleoside therapeutic compositions, combinations and uses related thereto
CN113278040B (zh) * 2021-06-16 2022-07-05 苏州立新制药有限公司 5’-异丁酰基-n4-羟基胞苷的制备方法
CN117642410A (zh) * 2021-06-18 2024-03-01 苏州春海生物医药有限公司 N4-羟基胞苷的酯衍生物及其用途
WO2023012329A1 (en) 2021-08-06 2023-02-09 Intervet International B.V. Method of treating veterinary viral diseases
CA3230382A1 (en) 2021-09-08 2023-03-16 Aligos Therapeutics, Inc. Modified short interfering nucleic acid (sina) molecules and uses thereof
CN113880902A (zh) * 2021-10-26 2022-01-04 江苏睿实生物科技有限公司 一种Molnupiravir药物中间体及其制备方法
US11541071B1 (en) * 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
CN114478658A (zh) * 2022-02-22 2022-05-13 苏州正济药业有限公司 一种莫那比拉韦的合成方法
WO2023202604A1 (zh) * 2022-04-20 2023-10-26 中国科学院上海药物研究所 抗病毒核苷类似物及其药物组合物和用途
WO2024129985A2 (en) * 2022-12-14 2024-06-20 Lakewood Amedex, Inc. Antiviral compounds, compositions, and uses thereof
KR20250127754A (ko) 2022-12-23 2025-08-26 메이지 세이카 파루마 가부시키가이샤 에버멕틴 유도체
WO2024182446A2 (en) 2023-02-28 2024-09-06 Aligos Therapeutics, Inc. Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof
US20240352464A1 (en) 2023-03-07 2024-10-24 Aligos Therapeutics, Inc. Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
MX2025013248A (es) * 2023-05-05 2026-02-03 Univ Emory Composiciones terapéuticas de nucleótidos y nucleósidos que contienen 4'-halógeno y usos relacionados con estas
CN117567310A (zh) * 2023-11-28 2024-02-20 重庆智合生物医药有限公司 一种神经酰胺np1的合成方法
WO2025144872A2 (en) * 2023-12-29 2025-07-03 Adarx Pharmaceuticals, Inc. Nucleoside-derived lipids for drug delivery
WO2026011167A1 (en) * 2024-07-05 2026-01-08 Emory University Thionucleosides as antiviral agents

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4207363A1 (de) * 1992-03-04 1993-09-09 Max Delbrueck Centrum Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung
EP1950563A3 (en) * 2002-09-11 2008-08-06 Michio Ishibashi Method for screening for a substance for promoting regeneration of macrophages
EP2068912A2 (en) * 2006-09-27 2009-06-17 Coley Pharmaceutical Group, Inc. Compositions of tlr ligands and antivirals
WO2009058800A2 (en) * 2007-10-29 2009-05-07 President And Fellows Of Harvard College Synthesis of nucleosides
EP2342616A2 (en) * 2008-09-23 2011-07-13 Alnylam Pharmaceuticals Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
MY171577A (en) 2011-12-20 2019-10-21 Hoffmann La Roche 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
CA2873315A1 (en) 2012-05-22 2013-11-28 Idenix Pharamaceuticals, Inc. D-amino acid compounds for liver disease
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
GEP201706757B (en) * 2012-12-21 2017-10-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
EP2981542B1 (en) * 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
EP2996695B1 (en) 2013-05-16 2022-04-13 Riboscience LLC 4'-fluoro-2'-methyl substituted nucleoside derivatives
HK1224229A1 (zh) * 2013-06-26 2017-08-18 Alios Biopharma, Inc. 取代的核苷，核苷酸及其类似物
WO2015051169A2 (en) * 2013-10-02 2015-04-09 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
EP3055319A4 (en) * 2013-10-11 2018-01-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
LT3160476T (lt) * 2014-06-24 2021-04-12 Janssen Biopharma, Inc. Pakeistieji nukleozidai, nukleotidai ir jų analogai, skirti naudoti virusinių infekcijų gydyme
TN2016000566A1 (en) 2014-06-24 2018-04-04 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
WO2016134054A1 (en) * 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
WO2016134056A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
EA201890454A1 (ru) * 2015-08-06 2018-07-31 Чимерикс, Инк. Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств
WO2017040892A1 (en) * 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
WO2017040895A1 (en) 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
WO2017040896A1 (en) * 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
US11963972B2 (en) * 2016-03-23 2024-04-23 Emory University Antiviral agents and nucleoside analogs for treatment of Zika virus
EP3471738A4 (en) * 2016-06-20 2020-01-01 Merck Sharp & Dohme Corp. CYCLIC PHOSPHONATE-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR USE THEREOF FOR TREATING VIRUS DISEASES

Similar Documents

Publication Publication Date Title
JP2021517132A5 (https=)
JPWO2019173602A5 (https=)
GB2589205A (en) 4'-halogen containing nucleotide and nucleotide therapeutic compositions and uses related thereto
ES2380887T3 (es) Formulaciones farmacéuticas de inhibidores de la HDAC
CN108135964B (zh) 谷胱甘肽制剂和使用方法
ES2656901T3 (es) Una formulación estabilizada de pemetrexed
JP2008522981A5 (https=)
HRP20180220T1 (hr) Derivati pirolapimiridina koji se koriste u liječenju virusnih infekcija
JP2011051993A5 (https=)
JP2008518950A5 (https=)
JP2016504284A5 (https=)
AR055395A1 (es) Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
HRP20220278T1 (hr) 2'-supstituirani-n6-supstituirani purinski nukleotidi za liječenje bolesti izazvanih rnk virusima
AR055669A1 (es) Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
AR064370A1 (es) Nitroderivados de bencenosulfonamidas sustituidas como inhibidores de anhidrasa carbonica composiciones farmaceuticas que los comprenden kits farmaceuticos para su administracion y su uso en la preparacion de un medicamento para el tratamiento del cancer y de trastornos oculares
EP2307056A2 (en) Stabilized aqueous formulation containing paracetamol
IL301015A (en) Formulations of anti-viral compounds
JP2012530061A5 (https=)
BR112012029212A2 (pt) formulação de paracetamol injetável pronta para o uso estável
MX2019003698A (es) Composicion que comprende al menos una sal farmaceuticamente aceptable de elafibranor soluble en medio acuoso que muestra una absorcion intestinal mejorada.
JP2018521969A5 (https=)
JP2013536257A5 (https=)
RU2008147216A (ru) Жидкая лекарственная композиция
ES2318277T3 (es) Composicion farmaceutica que compresnde acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico.
US20190328663A1 (en) Liposomes for the treatment of viral infections